Journal of Andrology Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Published-Ahead-of-Print September 4, 2008, DOI:10.2164/jandrol.108.005751
Journal of Andrology, Vol. 30, No. 1, January/February 2009
Copyright © American Society of Andrology
DOI: 10.2164/jandrol.108.005751

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
30/1/23    most recent
Author Manuscript (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Traish, A. M.
Right arrow Articles by Guay, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Traish, A. M.
Right arrow Articles by Guay, A.

Review

The Dark Side of Testosterone Deficiency: II. Type 2 Diabetes and Insulin Resistance

ABDULAMAGED M. TRAISH*, FARID SAAD{dagger},{ddagger} AND ANDRE GUAY§

From the * Department of Biochemistry and Urology, Boston University School of Medicine, Boston, Massachusetts; {dagger} Bayer-Schering Pharma, Men's Healthcare, Berlin, Germany; the {ddagger} Gulf Medical College School of Medicine, Ajman, United Arab Emirates; and the § Department of Endocrinology, Center for Sexual Function, Lahey Clinic, Peabody, Massachusetts.

Correspondence to: Dr Abdulmaged M. Traish, Professor of Biochemistry & Urology, Director, Laboratories for Sexual Medicine, Institute for Sexual Medicine, Boston University School of Medicine, Center for Advanced Biomedical Research, 700 Albany Street, W607, Boston, MA 02118 (e-mail: atraish{at}bu.edu).



Abstract

A considerable body of evidence exists suggesting a link among reduced testosterone plasma levels, type 2 diabetes (T2D), and insulin resistance (IR). Hypogonadal men are at higher risk for T2D. Here we evaluate the relationships between testosterone, metabolic syndrome (MetS), T2D, and IR and discuss the relationships among androgen deficiency and these factors, especially as it ultimately relates to the development of cardiovascular disease and erectile dysfunction (ED). Thus, a comprehensive literature search was carried out using PubMed, and relevant articles pertinent to androgen deficiency, T2D, IR, MetS, and ED were reviewed and discussed. Low testosterone precedes elevated fasting insulin, glucose, and hemoglobin A1c (HbA1C) values and may even predict the onset of diabetes. Treatment of prostate cancer patients with surgical or medical castration exacerbates IR and glycemic control, strengthening the link between testosterone deficiency and onset of T2D and IR. Androgen therapy of hypogonadal men improves insulin sensitivity, fasting glucose, and HbA1c levels. We suggest that androgen deficiency is associated with IR, T2D, MetS, and with increased deposition of visceral fat, which serves as an endocrine organ, producing inflammatory cytokines and thus promoting endothelial dysfunction and vascular disease.

     Key words: Erectile dysfunction, androgen deficiency, metabolic syndrome, vascular disease






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by The American Society of Andrology.